Targeted nalmefene with simple medical management in the treatment of heavy drinkers: A randomized double-blind placebo-controlled multicenter study

Alcoholism: Clinical and Experimental Research

Volumn 31, Issue 7, 2007, Pages 1179-1187

  Karhuvaara, Sakari ^a   Simojoki, Kaarlo ^b   Virta, Antti ^c   Rosberg, Markus ^d   Löyttyniemi, Eliisa ^e   Nurminen, Tommi ^e   Kallio, Antero ^e   Mäkelä, Rauno ^a  

^a Espoo A Clinic ^*  (Finland)

^b Kettutie A Clinic   (Finland)

^c Biotie Therapies Corp   (Finland)

^d Biotie Therapies Corp   (Finland)

^e A klinikkasaatio Finland   (Finland)

Author keywords

Alcoholism; Clinical Trial; Drinking Reduction; Nalmefene; Pharmacotherapy

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; NALMEFENE; PLACEBO;

ADULT; AGITATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOLISM; ANXIETY; APPETITE; ARTICLE; AUDITORY HALLUCINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISSOCIATIVE DISORDER; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENERAL PRACTICE; HANGOVER; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MUSCLE TIGHTNESS; NAUSEA; NIGHTMARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOSOCIAL REHABILITATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SWEATING; VISUAL HALLUCINATION; VOMITING;

ALCOHOL DRINKING; ALCOHOLISM; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; FINLAND; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; NAUSEA; PATIENT COMPLIANCE; PLACEBOS; SLEEP INITIATION AND MAINTENANCE DISORDERS; SUBSTANCE ABUSE TREATMENT CENTERS; TEMPERANCE; TREATMENT OUTCOME;

EID: 34250616600     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2007.00401.x     Document Type: Article

References (37)

1. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK (1999) Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 156 : 1758 1764.
2. Anton RF, Pettinati H, Zweben A, Kranzler HR, Johnson B, Bohn MJ, McCaul ME, Anthenelli R, Salloum I, Galloway G, Garbutt J, Swift R, Gastfriend D, Kallio A, Karhuvaara S (2004) A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol 24 : 421 428.
3. Balldin J, Berglund M, Borg S, Mansson M, Bendtsen P, Franck J, Gustafsson L, Halldin J, Nilsson LH, Stolt G, Willander A (2003) A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res 27 : 1142 1149.
4. Beck AT, Steer RA (1993) Beck Anxiety Inventory Manual. The Psychological Corporation, San Antonio.
5. Beck AT, Steer RA, Brown GK (1996) Beck Depression Inventory - Second Edition Manual. The Psychological Corporation, San Antonio.
6. Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, Labriola D, Marshall J, Moncrieff J, Morgan MY, Peters T, Ritson B (2000a) A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 35 : 587 593.
7. Chick J, Howlett H, Morgan MY, Ritson B (2000b) United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 35 : 176 187.
8. Drinker Inventory of Consequences (DrInC) (1993) An Instrument for Assessing Adverse Consequences of Alcohol Abuse. U.S. Government Printing Office, Washington, DC.
9. Drobes DJ, Anton RF, Thomas SE, Voronin K (2003) A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene. Neuropsychopharmacology 28 : 755 764.
10. Finney JW, Moyer A, Swearingen CE (2003) Outcome variables and their assessment in alcohol treatment studies: 1968-1998. Alcohol Clin Exp Res 27 : 1671 1679.
11. Gal TJ, DiFazio CA, Dixon RB (1986) Prolonged blockade of opioid effect with oral nalmefene. Clin Pharmacol Ther 40 : 537 542.
12. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW, Vivitrex Study Group (2005) Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 293 : 1617 1625. Erratum in: JAMA. 2005;293:1978.
13. Heinala P, Alho H, Kiianmaa K, Lonnqvist J, Kuoppasalmi K, Sinclair JD (2001) Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double blind, placebo-controlled trial. J Clin Psychopharmacol 21 : 287 292.
14. Ingman K, Hagelberg N, Aalto S, Någren K, Juhakoski A, Karhuvaara S, Kallio A, Oikonen V, Hietala J, Scheinin H (2005) Prolonged central μ-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacology 30 : 2245 2253.
15. Johnson B, Ait-Daoud N (2000) Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology (Berlin) 149 : 327 344.
16. Kim S, Wagner HNJ, Villemagne VL, Kao PF, Dannals RF, Ravert HT, Joh T, Dixon RB, Civelek AC (1997) Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system. J Nucl Med 38 : 1726 1731.
17. Koob GF (2000) Neurobiology of addiction. Toward the development of new therapies. Ann NY Acad Sci 909 : 170 185.
18. Koob GF, Ahmed SH, Boutrel B, Chen SA, Kenny PJ, Markou A, O'Dell LE, Parsons LH, Sanna PP (2004) Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci Biobehav Rev 27 : 739 749.
19. Kranzler HR, Armeli S, Tennen H, Blomqvist O, Oncken C, Petry N, Feinn R (2003) Targeted naltrexone for early problem drinkers. J Clin Psychopharmacol 23 : 294 304.
20. Kranzler HR, Tennen H, Penta C, Bohn MJ (1997) Targeted naltrexone treatment of early problem drinkers. Addict Behav 22 : 431 436.
21. Kranzler HR, Wesson DR, Billot L, Drug Abuse Sciences Naltrexone Depot Study Group (2004) Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res 28 : 1051 1059.
22. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA, Group VANCS (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345 : 1734 1739.
23. Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB (1999) A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 56 : 719 724.
24. Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E (2001) Naltrexone for alcohol dependence: a randomized controlled trial. Addiction 96 : 1565 1573.
25. Northrop Grumman Corp 2005) Medical Dictionary for Regulatory Activities (subscription). Available at :
26. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992) Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 49 : 881 887.
27. Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P (1997) Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry 171 : 73 77.
28. Sass H, Soyka M, Mann K, Zieglgansberger W (1996) Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 53 : 673 680.
29. Skinner HA, Allen BA (1982) Alcohol dependence syndrome: measurement and validation. J Abnorm Psychol 91 : 199 209.
30. Sobell LC, Sobell MB (1992) Timeline followback: a technique for assessing self-reported ethanol consumption, in Measuring Alcohol Consumption: Psychosocial and Biological Methods (Allen J, Litten RZ eds), pp 41 72. Humana Press, Totowa, NJ.
31. Sobell LC, Sobell MB, Connors GJ, Agrawal S (2003) Assessing drinking outcomes in alcohol treatment efficacy studies: selecting a yardstick of success. Alcohol Clin Exp Res 27 : 1661 1666.
32. Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A (2000) Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 35 : 202 209.
33. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49 : 876 880.
34. Volpicelli JR, Pettinati HM, McLellan AT, O'Brien CP (2001) Combining medication and psychosocial Treatments for Addiction: The BRENDA Approach. The Guilford press, New York, NY.
35. Wang SJ, Winchell CJ, McCormick CG, Nevius SE, O'Neill RT (2002) Short of complete abstinence: an analysis exploration of multiple drinking episodes in alcoholism treatment trials. Alcohol Clin Exp Res 26 : 1803 1809.
36. Weiss F, Porrino L (2002) Behavioral neurobiology of alcohol addiction: recent advances and challenges. J Neurosci 22 : 3332 3337.
37. Whitworth AB, Fischer F, Lesch O, Nimmerrichter A, Oberbauer H, Platz T, Potgieter A, Walter H, Fleischhacker WW (1996) Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 347 : 1438 1442.